Gram-positive Bacterial Infections Market Size, Share, Competitive Landscape and Trend Analysis Report, by Drug Type, by Disease and, by Route of Administration : Global Opportunity Analysis and Industry Forecast, 2023-2032

Bacteria is a class of micro-organisms that play an important role in the development of various infectious disease to the human being and animal kingdom. Bacteria classified on the basis of gram staining test. It is divided into two different types, such as gram-positive bacteria and gram-negative bacteria. Gram-positive bacteria have cell wall composed of thick layers peptidoglycan. Gram-positive bacteria are rod shapes, they're known as bacilli. These bacteria are present on the skin, sometime it cause serious medical conditions. This bacteria observed as violet purple colored stains which give the positive result in the gram stain test. It is observed under microscope. 

Gram-positive bacteria responsible for infecting humans and animals with variety of acute and chronic diseases. These bacteria causes various infectious diseases such as MRSA, pneumonia, sepsis, sinusitis, cellulitis, otitis, pharyngitis, impetigo, etc. For the treatment of this infection diseases various antibiotic and antifungal drugs are introduce in the gram positive infectious market such as B-Lactam, quinolones, macrolides, tetracycline, aminoglycosides, sulphonamides and phenicols. Gram-positive bacterial infection drugs kill the gram-positive bacterial infections including MRSA infections, sinusitis, and pneumonia. These drugs act by various mechanisms such as inhibition of cell wall synthesis, inhibition of protein biosynthesis, and inhibition of DNA replication. 

COVID-19 Scenario Analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future. 

Recently, ongoing outbreak of COVID-19 impacted on gram positive bacterial infection market. Covid-19 started as a cluster of pneumonia cases with an unknown cause. The cause of the pneumonia was found to be a new virus. Severe Acute Respiratory Syndrome Coronavirus 2. The novel coronavirus belongs to the family of Coronaviridae and genus beta coronavirus, comprising vertebrate respiratory viruses including HCoV-OC43, responsible for 10% cases of common cold. Recently there is no availability of effective gram positive infection drug in the market that help to kill the corona virus. Various pharmaceutical companies’ of scientist, researcher undertaken initiative to develop the drug product that permanently kill the coronavirus. 

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

Globally, North America and Europe are the most dominating markets due to the increasing incidence of various gram-positive bacterial infections, and presence of major market player.  However, Asia-Pacific are expected to show profitable growth due to increasing occurrence of diseases, increasing awareness amongst the population about the diseases caused by gram-positive bacteria and their chronic effects.

As per the WHO report, in 2018, around 1.3 million people is died due to the tuberculosis, it is the second greatest killer across the globe. For the treatment of bacterial infectious disease various schemes are introduce by the WHO, which includes “DOTS” and “Stop TB Strategy” (particular for tuberculosis), which helps in growing awareness amongst the population, that drive the growth of the market.

The factors such as Growing incidence of various gram positive bacterial infections, increasing R&D activities, increasing awareness about infectious diseases rising investment in healthcare, rapidly increasing in antibacterial resistance, rising government initiatives, increasing investment in R&D activities, newer bacterial infection treatment and infection control in healthcare settings are majorly drive the growth of gram positive bacterial infection market. However, the factors that restrain the growth of gram positive bacterial infection such as stringent government regulation, high cost of treatment and R&D, ignorance towards the symptoms, etc.

New Product launch to flourish the market:

Major Key market manufacturer have been focusing on producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications. Recently the product available in the market to treat gram positive bacterial infection include LTX-109, PYN-6, RX-P792, XF-70, and TD-1607, etc. 

In 2019, “Basilea” get a positive results of phase 3 TARGET study with antibiotic “Ceftobiprole”. This drug used for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

In 2019, “Bayer” has launched natural dipeptide antibiotic TAN 1057 AB which shows outstanding antibacterial activity against staphylococci including methicillin resistant Staphylococcus aureus. 

In 2019, AstraZeneca get approval from USFDA for the pivotal Phase III studies of “RECLAIM-1 and RECLAIM-2”, drug product which investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections. 

Key benefits of the report:

• This study presents the analytical depiction of the global gram-positive bacterial infections market along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global gram-positive bacterial infections market share.
• The current market is quantitatively analyzed to highlight the global gram-positive bacterial infections market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed global gram-positive bacterial infections market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Gram-Positive Bacterial Infections Market research report:

• Who are the leading market players active in gram-positive bacterial infections market?
• What are the current trends will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities in the market?
• What are the projections for the future that will help in taking further strategic steps?

  Gram-positive Bacterial Infections Market Report Highlights

Aspects	Details
By Drug Type	Antibiotic Antifungal Others
By Disease	Gram-Positive Bacterial Infections MRSA Pneumonia Sepsis Sinusitis Cellulitis Otitis Pharyngitis Impetigo Others
By Route of Administration	Enteral Parenteral Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	GSK plc., Basilea Pharmaceuticals Ltd., Cubist Pharmaceuticals, TAXIS Pharmaceuticals, Inc., Novabiotics Ltd., Bayer AG, Pfizer, Inc., Sanofi, Theravance, Inc., Aphios Corporation

^*Terms and Conditions Apply